Mohammed Osman, MD
Clinical Cardiac Electrophysiology · Cleveland, OHNPI 1194934117
Payments from drug & device makers
Across 242 payments — averaging $96.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$12K
- Abbott$7K
- Abiomed$1K
- Boston Scientific$425
- Atricure, Inc.$347
- Pfizer$283
- plus $2K from 24 others
Across 1 payment — averaging $134.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$134
What the payments were for
- Consulting fees$3,50015%
- Speaking & faculty fees$3,71316%
- Travel & lodging$6,05226%
- Food & beverage$9,52541%
- Education$4672%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 82 | $11,580 |
| Abbott | 47 | $7,220 |
| Abiomed | 9 | $1,214 |
| Boston Scientific | 8 | $425 |
| Atricure, Inc. | 3 | $347 |
| Pfizer | 17 | $283 |
| Impulse Dynamics (USA) Inc. | 4 | $240 |
| Novartis | 12 | $212 |
| Shockwave Medical, Inc | 1 | $180 |
| Biosense Webster, Inc. | 2 | $165 |
| Insmed, Inc. | 1 | $156 |
| Cvrx, Inc. | 3 | $156 |
| Johnson & Johnson | 9 | $144 |
| E.r. Squibb & Sons, L.L.C. | 8 | $130 |
| Regeneron Healthcare Solutions, Inc. | 6 | $113 |
| Amgen | 6 | $101 |
| AstraZeneca | 5 | $84 |
| Alnylam Pharmaceuticals Inc. | 3 | $75 |
| Stryker | 1 | $72 |
| Terumo Medical Corporation | 1 | $63 |
| Boehringer Ingelheim | 3 | $52 |
| Angiodynamics, Inc. | 1 | $47 |
| Biotronik Inc. | 1 | $47 |
| Amarin Pharma, Inc. | 2 | $38 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $26 |
| Cordis US CORP. | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $18 |
| Portola Pharmaceuticals, LLC | 1 | $17 |
| Livanova USA, Inc. | 1 | $14 |
| Elutia, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONYX FRONTIER$3,843
- CardioMEMS HF System$3,500
- EVERA MRI XT DR SURESCAN$1,484
- Arctic Front$1,441
- AVEIR$1,396
- Impella$951
- HeartMate 3 Left Ventricular Dev$732
- Ensite Cardiac Mapping System$608
- DIAMONDTEMP BIDIRECTIONAL ABLATION CATHETER$520
- Micra$512
- Octopus$275
- OPTIMIZER$266
- SelectSecure$265
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$181
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$180
- NAVITOR$159
- Arikayce$156
- AZURE XT DR MRI SURESCAN$154
- ATRICURE SYNERGY ABLATION SYSTEM$148
- AVVIGO Guidance System$148
How this compares
$23,257 in reported general payments places this provider in the 40th percentile of 159 clinical cardiac electrophysiology providers in Ohio.
See all clinical cardiac electrophysiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 184 | $154,248 |
| EntrestoSacubitril/Valsartan | 93 | $95,665 |
| FarxigaDapagliflozin Propanediol | 45 | $42,624 |
| Repatha SureclickEvolocumab | 42 | $42,067 |
| Repatha PushtronexEvolocumab | 48 | $31,314 |
| JardianceEmpagliflozin | 18 | $21,477 |
| Praluent PenAlirocumab | 25 | $12,512 |
| Amiodarone Hcl | 40 | $2,296 |
| Atorvastatin Calcium | 242 | $1,458 |
| Metoprolol Succinate | 119 | $1,196 |
| ClopidogrelClopidogrel Bisulfate | 123 | $562 |
| Rosuvastatin Calcium | 43 | $534 |
| Losartan Potassium | 65 | $429 |
| Metoprolol Tartrate | 118 | $422 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 71 | $408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $283 | $154,248184 claims |
| NovartisEntresto | $212 | $95,66593 claims |
| AstraZenecaFarxiga | $84 | $42,62445 claims |
| Boehringer IngelheimJardiance | $52 | $21,47718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 159 clinical cardiac electrophysiology providers in Ohio.
Other clinical cardiac electrophysiology in Cleveland
- Walid SalibaCleveland$5.3M
- Bruce WilkoffCleveland$1.4M
- Ayman HusseinCleveland$1.3M
- Thomas CallahanCleveland$805K
- Judith MackallCleveland$534K
- Shady NakhlaCleveland$380K
- Mauricio ArrudaCleveland$254K
- Albert WaldoCleveland$127K
- Otto CostantiniCleveland$117K
- Bryan BaranowskiCleveland$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.